Sign Out
The adverse reactions notified in clinical trials in children (n=460) were similar to those observed in adults.
The table as follows includes the adverse reactions reported in clinical trials and during the post-marketing phase, using the following convention: very frequent (≥1/10), frequent (≥1/100 to <1/10), infrequent (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and frequency not known (cannot be estimated from the available data). (See table.)
Click on icon to see table/diagram/image
View ADR Reporting Link
Continue with Google